Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells

Cancer Research

Volumn 63, Issue 16, 2003, Pages 4984-4989

  Villar Garea, Ana ^a   Fraga, Mario F ^a   Espada, Jesus ^a   Esteller, Manel ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

5 METHYLCYTOSINE; DNA; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE INHIBITOR; ENZYME INHIBITOR; PROCAINE; RETINOIC ACID RECEPTOR BETA; RETINOIC ACID RECEPTOR BETA2; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL STRAIN MCF 7; CPG ISLAND; DEMETHYLATION; DNA CONTENT; DNA DEGRADATION; DRUG EFFECT; DRUG EFFICACY; GENE EXPRESSION; GENE SILENCING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MITOSIS INHIBITION; PRIORITY JOURNAL; PROMOTER REGION;

ANTINEOPLASTIC AGENTS; CPG ISLANDS; DNA; DNA METHYLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; GENES, TUMOR SUPPRESSOR; HUMANS; PROCAINE; RECEPTORS, RETINOIC ACID; TUMOR CELLS, CULTURED;

EID: 0041939756     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Jones, P. A., and Baylin, S. B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet., 3: 415-428, 2002.
2. Esteller, M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene, 21: 5427-5440. 2002.
3. Costello, J. F., Fruhwald, M. C., Smiraglia, D. J., Rush, L. J., Robertson, G. P., Gao, X., Wright, F. A., Feramisco, J. D., Peltomaki, P., Lang, J. C., Schuller, D. E., Yu, L., Bloomfield, C. D., Caligiuri, M. A., Yates, A., Nishikawa, R., Su Huang, H., Petrelli, N. J., Zhang, X., O'Dorisio, M. S., Held, W. A., Cavence, W. K., and Plass, C. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat. Genet., 24: 132-138, 2000.
4. Esteller, M., Com, P. G., Baylin, S. B., and Herman, J. G. A gene hypermethylation profile of human cancer. Cancer Res., 61: 3225-3229, 2001.
5. Jones, P. A. Effects of 5-azacytidine and its 2′-deoxyderivative on cell differentiation and DNA methylation. Pharmacol. Ther., 28: 17-27, 1985.
6. Herman, J. G., Umar, A., Polyak, K., Graff, J. R., Ahuja, N., lssa, J. P., Markowitz, S., Willson. J. K., Hamilton, S. R., Kinzler, K. W., Kane, M. F., Kolodne, R. D., Vogelstein, B., Kunkel, T. A., and Baylin, S. B. Incidence and functional consequences of hMLHI promoter hypermethylation in colorectal carcinoma. Proc. Natl. Acad. Sci. USA, 95: 6870-6875, 1998.
7. Esteller, M., Cordon-Cardo, C., Com, P. G., Meltzer, S. J., Pohar, K. S., Watkins, D. N., Capella, G., Peinado, M. A., Matias-Guiu, X., Prat, J., Baylin, S. B., and Herman, J. G. p14ARF silencing by promoter hypermethylation mediates abnormal intracellular localization of MDM2. Cancer Res., 61: 2816-2821, 2001.
8. Rhee, I., Bachman, K. E., Park, B. H., Jair, K. W., Yen, R. W., Schuebel, K. E., Cui, H., Feinberg, A. P, Lengauer, C., Kinzler, K. W., Baylin, S. B., and Vogelstein, B. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature (Lond.), 416: 552-556, 2002.
9. Comacchia, E., Golbus, J., Maybaum, J., Strahler, J., Hanash, S., and Richardson. B. Hydralazine and procainamide inhibit T cell DNA methylation and induce auto-reactivity. J. Immunol., 140: 2197-2200, 1988.
10. Scheinbart, L. S., Johnson, M. A., Gross, L. A., Edelstein, S. R., and Richardson, B. C. Procainamide inhibits DNA methyltransferase in a human T cell line. J. Rheumatol., 18: 530-534, 1991.
11. Lin, X., Asgari, K., Putzi, M. J., Gage, W. R., Yu, X., Comblatt, B. S., Kumar, A., Piantadosi, S., DeWeese, T. L., De Marzo, A. M., and Nelson, W. G. Reversal of GSTP1 CpG island hypermethylation and reactivation of pi-class glutathione S-transferase (GSTP1) expression in human prostate cancer cells by treatment with procainamide. Cancer Res., 61: 8611-8616, 2001.
12. Thomas, T. J., and Messner, R. P. Effects of lupus-inducing drugs on the B to Z transition of synthetic DNA. Arthritis Rheum., 29: 638-645, 1986.
13. Zacharias, W., and Koopman, W. J. Lupus-inducing drugs alter the structure of supercoiled circular DNA domains. Arthritis Rheum., 33: 366-374, 1990.
14. Esteller, M., Fraga, M. F., Guo, M., Garcia-Foncillas, J., Hedenfalk, I., Godwin, A. K.; Trojan, J., Vaurs-Barriere, C., Bignon, Y. J., Ramus, S., Benitez, J., Caldes, T., Akiyama, Y., Yuasa, Y., Launonen, V., Canal, M. J., Rodriguez, R., Capella, G., Peinado, M. A., Borg, A., Aaltonen, L. A., Ponder, B. A., Baylin, S. B., and Herman, J. G. DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum. Mol. Genet., 10: 3001-3007, 2001.
15. Fraga, M. F., Uriol, E., Borja Diego, L., Berdasco, M., Esteller, M., Canal, M J., and Rodriguez, R. High-performance capillary electrophoretic method for the quantification of 5-methyl 2′-deoxycytidine in genomic DNA: application to plant, animal and human cancer tissues. Electrophoresis, 23: 1677-1681, 2002.
16. Herman, J. G., Graff, J. R., Myohanen, S., Nelkin, B. D., and Baylin, S. B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA, 93: 9821-9826, 1996.
17. Arapshian, A., Kuppumbatti, Y. S., and Mira-y-Lopez, R. Methylation of conserved CpG sites neighboring the beta retinoic acid response element may mediate retinoic acid receptor β gene silencing in MCF-7 breast cancer cells. Oncogene, 19: 4066-4070, 2000.
18. Esteller, M., Sparks, A., Toyota, M., Sanchez-Cespedes, M., Capella, G., Peinado, M. A., Gonzalez, S., Tarafa, G., Sidransky, D., Meltzer, S. J., Baylin, S. B., and Herman, J. G. Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res., 60: 4366-4371, 2000.
19. Esteller, M., Guo, M., Moreno, V., Peinado, M. A., Capella, G., Galm, O., Baylin, S. B., and Herman, J. G. Hypermethylation-associated inactivation of the cellular retinol-binding-protein 1 gene in human cancer. Cancer Res., 62: 5902-5905, 2002.
20. Bovenzi, V., and Momparler, R. L. Antineoplastic action of 5-aza-2′-eoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor β and estrogen receptor a genes in breast carcinoma cells. Cancer Chemother. Pharmacol., 48: 71-76, 2001.
21. Bolos, V., Peinado, H., Perez-Moreno, M. A., Fraga, M. F., Esteller, M., and Cano, A. The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors. J. Cell Sci., 499-511, 2002.
22. Fraga, M. F., Ballestar, E., Montoya, G., Taysavang, P., Wade, P., and Esteller, M. The affinity of different MBD proteins for specific methylated loci depends on their intrinsic binding properties. Nucleic Acids Res., 31: 1765-1774, 2003.
23. Sirchia, S. M., Ferguson, A. T., Sironi, E., Subramanyan, S., Orlandi, R., Sukumar, S., and Sacchi, N. Evidence of epigenetic changes affecting the chromatin state of retinoic acid receptor β2 promoter in breast cancer cells. Oncogene, 19: 1556-1563, 2000.
24. Paz, M. F., Fraga, M. F., Avila, S., Guo, M., Pollan, M., Herman, J. G., and Esteller, M. A systematic profile of DNA methylation in human cancer cell lines. Cancer Res., 63: 1114-1121, 2003.
25. Virmani, A. K., Rathi, A., Zochbauer-Muller, S., Sacchi, N., Fukuyama, Y., Bryant, D., Maitra, A., Heda, S., Fong, K. M., Thunnissen, F., Minna, J. D., and Gazdar, A. F. Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas. J. Natl. Cancer Inst. (Bethesda), 92: 1303-1307, 2000.
26. Widschwendter, M., Berger, J., Hermann, M., Muller, H. M., Amberger, A., Zeschnigk, M., Widschwendter, A., Abendstein, B., Zeimet, A. G., Daxenbichler, G., and Marth, C. Methylation and silencing of the retinoic acid receptor-β2 gene in breast cancer. J. Natl. Cancer Inst. (Bethesda), 92: 826-832, 2000.
27. Esteller, M., Fraga, M. F., Paz, M. F., Campo, E., Colomer, D., Novo, F. J., Calasanz, M. J., Galm, O., Guo, M., Benitez, J., and Herman, J. G. Cancer epigenetics and methylation. Science (Wash. DC), 297: 1807-1808, 2002.
28. Oohara, I., and Wada, A. Spectroscopic studies on histone-DNA interactions. II. Three transitions in nucleosomes resolved by salt-titration. J. Mol. Biol., 196: 399-411, 1987.
29. Cameron, E. E., Bachman, K. E., Myohanen, S., Herman, J. G., and Baylin, S. B. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet., 21: 103-107, 1999.
30. Chlebowski, R. T., Block, J. B., Cundiff, D., and Dietrich, M. F. Doxorubicin cytotoxicity enhanced by local anesthetics in a human melanoma cell line. Cancer Treat. Rep., 66: 121-125, 1982.
31. Esposito, M., Fulco, R. A., Collecchi, P., Zicca, A., Cadoni, A., Merlo, F., Rosso, R., and Sobrero, A. Improved therapeutic index of cisplatin by procaine hydrochloride. J. Natl. Cancer Inst. (Bethesda), 82: 677-684, 1990.
32. Viale, M., Pastrone, I., Pellecchia, C., Vannozzi, M. O., Cafaggi, S., and Esposito, M. Combination of cisplatin-procaine complex DPR with anticancer drugs increases cytotoxicity against ovarian cancer cell lines. Anticancer Drugs, 9: 457-463, 1998.
33. Mizuno, S., and Ishida, A. Selective enhancement of the cytotoxicity of the bleomycin derivative, peplomycin, by local anesthetics alone and combined with hyperthermia. Cancer Res., 42: 4726-4729, 1982.
34. Hidvegi, E. J., Yatvin, M. B., Dennis, W. H., and Hidvegi, E. Effect of altered membrane lipid composition and procaine on hyperthermic killing of ascites tumor cells. Oncology, 37: 360-363, 1980.
35. Yau, T. M., and Kim, S. C. Local anaesthetics as hypoxic radiosensitizers, oxic radioprotectors and potentiators of hyperthermic killing in mammalian cells. Br. J. Radiol., 53: 687-692, 1980.
36. Jackson-Grusby, L., Laird, P. W., Magge, S. N., Moeller, B. J., and Jaenisch, R. Mutagenicity of 5-aza-2′-deoxycytidine is mediated by the mammalian DNA methyltransferase. Proc. Natl. Acad. Sci. USA, 94: 4681-4685, 1997.